Simultaneous elimination of all NIK regulating components is probably excessive since depletion of any one of those components can break this degradation-promoting circle as seen in multiple myeloma patients that harbor mutations in individual components, IAP antagonists that specifically target c-IAP1/2 proteins or BR3 signaling that selectively recruits TRAF3 (29, 31, 32, 38, 49, 50). Here, BIRC2 is linked to plasma cell myeloma.